Insmed Incorporated

LSE:0JAV Stock Report

Market Cap: US$14.5b

Insmed Valuation

Is 0JAV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0JAV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$577.12
Fair Value
85.9% undervalued intrinsic discount
16
Number of Analysts

Below Fair Value: 0JAV ($81.39) is trading below our estimate of fair value ($577.12)

Significantly Below Fair Value: 0JAV is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0JAV?

Key metric: As 0JAV is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0JAV. This is calculated by dividing 0JAV's market cap by their current revenue.
What is 0JAV's PS Ratio?
PS Ratio40x
SalesUS$363.71m
Market CapUS$14.54b

Price to Sales Ratio vs Peers

How does 0JAV's PS Ratio compare to its peers?

The above table shows the PS ratio for 0JAV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.9x
GNS Genus
1.7x3.5%UK£1.2b
OXB Oxford Biomedica
3.8x18.3%UK£365.6m
BVXP Bioventix
11.5xn/aUK£156.6m
AVCT Avacta Group
6.7x-7.1%UK£151.4m
0JAV Insmed
40x42.7%US$14.5b

Price-To-Sales vs Peers: 0JAV is expensive based on its Price-To-Sales Ratio (40x) compared to the peer average (5.9x).

Price to Sales Ratio vs Industry

How does 0JAV's PS Ratio compare vs other companies in the GB Biotechs Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
1.7x3.5%US$1.47b
OXB Oxford Biomedica
3.8x18.3%US$461.79m
TRX Tissue Regenix Group
1.3x15.1%US$40.49m
AREC Arecor Therapeutics
4x2.4%US$24.56m
0JAV 40.0xIndustry Avg. 9.0xNo. of Companies8PS01632486480+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0JAV is expensive based on its Price-To-Sales Ratio (40x) compared to the European Biotechs industry average (9x).

Price to Sales Ratio vs Fair Ratio

What is 0JAV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0JAV PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio40x
Fair PS Ratio17.8x

Price-To-Sales vs Fair Ratio: 0JAV is expensive based on its Price-To-Sales Ratio (40x) compared to the estimated Fair Price-To-Sales Ratio (17.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0JAV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$81.39
US$95.08
+16.8%
9.9%US$108.00US$67.26n/a16
Feb ’26US$78.37
US$88.14
+12.5%
10.4%US$105.00US$67.26n/a16
Jan ’26US$68.62
US$88.25
+28.6%
10.1%US$105.00US$67.26n/a17
Dec ’25US$75.52
US$89.40
+18.4%
8.1%US$105.00US$75.00n/a17
Nov ’25US$68.23
US$89.10
+30.6%
8.9%US$105.00US$74.00n/a17
Oct ’25US$72.50
US$87.50
+20.7%
8.5%US$103.00US$72.00n/a16
Sep ’25US$75.24
US$87.50
+16.3%
8.5%US$103.00US$72.00n/a16
Aug ’25US$74.78
US$83.75
+12.0%
9.7%US$102.00US$72.00n/a16
Jul ’25US$66.06
US$76.00
+15.0%
10.2%US$90.00US$60.00n/a16
Jun ’25US$54.38
US$62.38
+14.7%
17.7%US$77.00US$36.00n/a16
May ’25US$25.48
US$44.13
+73.2%
14.6%US$55.00US$35.00n/a16
Apr ’25US$27.23
US$43.67
+60.4%
15.5%US$55.00US$35.00n/a15
Mar ’25US$28.30
US$43.40
+53.4%
14.8%US$55.00US$35.00n/a15
Feb ’25US$28.18
US$42.54
+51.0%
16.6%US$55.00US$35.00US$78.3713
Jan ’25US$31.06
US$42.38
+36.5%
17.0%US$55.00US$35.00US$68.6213
Dec ’24US$26.02
US$41.42
+59.2%
15.6%US$52.00US$35.00US$75.5212
Nov ’24US$25.11
US$42.92
+70.9%
16.5%US$54.00US$35.00US$68.2312
Oct ’24US$25.62
US$42.58
+66.2%
17.5%US$54.00US$33.00US$72.5012
Sep ’24US$21.49
US$40.77
+89.8%
18.3%US$52.00US$30.00US$75.2413
Aug ’24US$21.69
US$40.38
+86.2%
19.3%US$52.00US$30.00US$74.7813
Jul ’24US$20.96
US$39.42
+88.1%
19.8%US$52.00US$28.00US$66.0612
Jun ’24US$18.59
US$39.15
+110.6%
19.3%US$52.00US$28.00US$54.3813
May ’24US$19.61
US$39.54
+101.6%
18.4%US$52.00US$28.00US$25.4813
Apr ’24US$17.11
US$39.38
+130.3%
18.8%US$52.00US$28.00US$27.2313
Mar ’24n/a
US$39.38
0%
18.8%US$52.00US$28.00US$28.3013
Feb ’24n/a
US$40.46
0%
17.5%US$52.00US$28.00US$28.1813
Analyst Price Target
Consensus Narrative from 16 Analysts
US$95.47
Fair Value
14.7% undervalued intrinsic discount
16
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/22 09:06
End of Day Share Price 2025/02/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Insmed Incorporated is covered by 31 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Neena Bitritto-GargBaird
Anita DushyanthBerenberg
Jason ZemanskyBofA Global Research